AU2005316972B2 - Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof - Google Patents

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof Download PDF

Info

Publication number
AU2005316972B2
AU2005316972B2 AU2005316972A AU2005316972A AU2005316972B2 AU 2005316972 B2 AU2005316972 B2 AU 2005316972B2 AU 2005316972 A AU2005316972 A AU 2005316972A AU 2005316972 A AU2005316972 A AU 2005316972A AU 2005316972 B2 AU2005316972 B2 AU 2005316972B2
Authority
AU
Australia
Prior art keywords
alkyl
indazol
dihydro
chromen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005316972A
Other languages
English (en)
Other versions
AU2005316972A1 (en
Inventor
Erol K. Bayburt
S. Brian Brown
F. Jerome Daanen
Arthur R. Gomtsyan
K. Tammie Jinkerson
R. John Koenig
Steve Latshaw
Chih-Hung Lee
Robert G. Schmidt Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2005316972A1 publication Critical patent/AU2005316972A1/en
Application granted granted Critical
Publication of AU2005316972B2 publication Critical patent/AU2005316972B2/en
Assigned to ABBVIE INC. reassignment ABBVIE INC. Request for Assignment Assignors: ABBOTT LABORATORIES
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005316972A 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof Ceased AU2005316972B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63063604P 2004-11-24 2004-11-24
US60/630,636 2004-11-24
PCT/US2005/042545 WO2006065484A2 (en) 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Publications (2)

Publication Number Publication Date
AU2005316972A1 AU2005316972A1 (en) 2006-06-22
AU2005316972B2 true AU2005316972B2 (en) 2011-11-10

Family

ID=36588346

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005316972A Ceased AU2005316972B2 (en) 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Country Status (13)

Country Link
US (2) US7812019B2 (enExample)
EP (2) EP2527339A1 (enExample)
JP (2) JP4932730B2 (enExample)
KR (2) KR101250824B1 (enExample)
CN (2) CN102161653A (enExample)
AU (1) AU2005316972B2 (enExample)
BR (1) BRPI0518581A2 (enExample)
CA (1) CA2588909A1 (enExample)
IL (1) IL183321A0 (enExample)
MX (1) MX2007006205A (enExample)
NZ (1) NZ555318A (enExample)
TW (1) TW200633712A (enExample)
WO (1) WO2006065484A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7957708B2 (en) * 2004-03-02 2011-06-07 Rosemount Inc. Process device with improved power generation
US8538560B2 (en) 2004-04-29 2013-09-17 Rosemount Inc. Wireless power and communication unit for process field devices
US8145180B2 (en) * 2004-05-21 2012-03-27 Rosemount Inc. Power generation for process devices
BRPI0518581A2 (pt) * 2004-11-24 2008-11-25 Abbott Lab compostos de cromanilurÉia que inibem o receptor do subtipo 1 do recepetor vanilàide (vr1) e usos destes
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
AR056320A1 (es) 2005-04-22 2007-10-03 Wyeth Corp Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
US8232309B2 (en) * 2005-10-28 2012-07-31 Abbott Laboratories Prodrugs of compounds that inhibit TRPV1 receptor
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
AU2007238071B2 (en) * 2006-04-18 2012-06-07 Abbvie Inc. Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
US7913566B2 (en) 2006-05-23 2011-03-29 Rosemount Inc. Industrial process device utilizing magnetic induction
WO2008059339A2 (en) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
CN101563318A (zh) * 2006-12-20 2009-10-21 艾博特公司 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
WO2009095726A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Acrylamide derivatives as vanilloid receptor 1 modulators
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
US8250924B2 (en) 2008-04-22 2012-08-28 Rosemount Inc. Industrial process device utilizing piezoelectric transducer
US8929948B2 (en) 2008-06-17 2015-01-06 Rosemount Inc. Wireless communication adapter for field devices
US8694060B2 (en) 2008-06-17 2014-04-08 Rosemount Inc. Form factor and electromagnetic interference protection for process device wireless adapters
CN102084307B (zh) 2008-06-17 2014-10-29 罗斯蒙特公司 用于具有低压本质安全钳的现场设备的rf适配器
US8847571B2 (en) * 2008-06-17 2014-09-30 Rosemount Inc. RF adapter for field device with variable voltage drop
WO2010023512A1 (en) * 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
JP2012505908A (ja) * 2008-10-17 2012-03-08 アボット・ラボラトリーズ Trpv1アンタゴニスト
TW201020236A (en) * 2008-10-17 2010-06-01 Abbott Lab TRPV1 antagonists
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN101654435B (zh) * 2009-06-09 2014-01-29 沈阳药科大学 N-苯甲基喹啉羧酸类化合物、组合物及其制备方法
US20100318007A1 (en) * 2009-06-10 2010-12-16 O'brien Donald J Electromechanical tactile stimulation devices and methods
US9674976B2 (en) 2009-06-16 2017-06-06 Rosemount Inc. Wireless process communication adapter with improved encapsulation
US8626087B2 (en) 2009-06-16 2014-01-07 Rosemount Inc. Wire harness for field devices used in a hazardous locations
US8648086B2 (en) 2009-08-24 2014-02-11 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US10761524B2 (en) 2010-08-12 2020-09-01 Rosemount Inc. Wireless adapter with process diagnostics
EP2688866A1 (en) 2011-03-25 2014-01-29 AbbVie Inc. Trpv1 antagonists
US9310794B2 (en) 2011-10-27 2016-04-12 Rosemount Inc. Power supply for industrial process field device
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
CN109574972A (zh) * 2018-07-13 2019-04-05 郑州大学 一种3-烷基取代-4-色满酮类化合物及其制备方法
PE20240017A1 (es) * 2020-09-30 2024-01-04 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
WO2025161263A1 (zh) * 2024-01-31 2025-08-07 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8900565A (nl) 1989-03-08 1990-10-01 Philips Nv Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode.
DE69029668T2 (de) * 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
WO1998008818A1 (en) 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO2001036403A1 (en) 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
CA2486092A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
BRPI0518581A2 (pt) * 2004-11-24 2008-11-25 Abbott Lab compostos de cromanilurÉia que inibem o receptor do subtipo 1 do recepetor vanilàide (vr1) e usos destes
US8232309B2 (en) * 2005-10-28 2012-07-31 Abbott Laboratories Prodrugs of compounds that inhibit TRPV1 receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOGNAR et al "Flavonoids, XII. Synthesis of 4-Ureido-flavan and di-(4-Flavanyl)-urea", Acts. Chim. Acad. Sci. Hung., 1963, Vol 35, Pages 223-224 *
WEBSTER et al "Reactions of Organic Peroxides. Part VIII. 1:3:3-Trimethylindan-lyl Hydroperoxide and its Conversion into 2:4:4-Trimethylchroman Derivatives", J. Chem. Soc. 1956, pages 4785-4791 *

Also Published As

Publication number Publication date
CN102161653A (zh) 2011-08-24
JP2008532925A (ja) 2008-08-21
EP2527339A1 (en) 2012-11-28
WO2006065484A2 (en) 2006-06-22
EP1844038A2 (en) 2007-10-17
TW200633712A (en) 2006-10-01
IL183321A0 (en) 2008-04-13
JP2012111766A (ja) 2012-06-14
US20060128689A1 (en) 2006-06-15
US8440691B2 (en) 2013-05-14
BRPI0518581A2 (pt) 2008-11-25
US7812019B2 (en) 2010-10-12
NZ555318A (en) 2011-01-28
KR20070086607A (ko) 2007-08-27
CA2588909A1 (en) 2006-06-22
KR101250824B1 (ko) 2013-04-05
JP4932730B2 (ja) 2012-05-16
AU2005316972A1 (en) 2006-06-22
WO2006065484A3 (en) 2009-02-19
US20110152250A1 (en) 2011-06-23
KR20120137420A (ko) 2012-12-20
MX2007006205A (es) 2009-02-13
CN101443327A (zh) 2009-05-27

Similar Documents

Publication Publication Date Title
AU2005316972B2 (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
US7622493B2 (en) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
EP1660455B1 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US20030158188A1 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US8501769B2 (en) Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
IL157659A (en) Spirotricyclic derivatives, medicinal preparations containing them, and their use as inhibitors of phosphodiesterase-7 and a method for their preparation
IL172457A (en) Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor for treating disorders caused by vanilloid receptor activity and process for their preparation
WO2005118573A1 (en) Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7615570B2 (en) Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2006054912A1 (fr) Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
KR19980702546A (ko) 4-아미노테트라히드로벤즈 이소옥사졸 또는 -이소티아졸 화합물
WO2011012674A1 (en) Dihydrobenzoindazoles
RU2081117C1 (ru) Производные лактама или их физиологические приемлемые соли или сольваты
KR20090034787A (ko) 모르피난 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ABBVIE INC.

Free format text: FORMER OWNER WAS: ABBOTT LABORATORIES

MK14 Patent ceased section 143(a) (annual fees not paid) or expired